Table 1 Clinicopathological data of the studied cases
From: Evaluation of ARK5 and SIRT3 expression in renal cell carcinoma and their clinical significance
| Â | Total number |
|---|---|
Gender | |
 Male | 36 (62.1%) |
 Female | 22 (37.9%) |
Age | |
 Mean ± SD | 57.3 ± 9.4 |
 Histological type clear | 32 (55.2%) |
 Papillary | 7 (12.1%) |
 Chromophobe | 16 (27.6%) |
 Others | 3 (5.2%) |
Grade | |
 1 | 15 (25.9%) |
 2 | 21 (36.2%) |
 3 | 14 (24.1%) |
 4 | 8 (13.8%) |
Apoptosis | |
 Mean ± SD | 2.5 ± 0.88 |
 Mitosis |  |
 Mean ± SD | 2.8 ± 1.1 |
Tumour extent | |
 T1 | 20 (34.5%) |
 T2 | 21 (36.2%) |
 T3 | 15 (25.9%) |
 T4 | 2 (3.4%) |
LN | |
 Negative | 56 (96.6%) |
 Positive | 2 (3.4%) |
Stage | |
 I | 20 (34.5%) |
 II | 20 (34.5%) |
 III | 16 (27.6%) |
 IV | 2 (3.4%) |
Response to chemotherapy | |
 No | 13 (29.5%) |
 Partial | 25 (56.8%) |
 Complete | 6 (13.6%) |